Tewari KS - Search Results

1

The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.

Haunschild CE, Tewari KS. Haunschild CE, et al. Among authors: tewari ks. Gynecol Oncol. 2021 Jan;160(1):333-345. doi: 10.1016/j.ygyno.2020.09.043. Epub 2020 Oct 11. Gynecol Oncol. 2021. PMID: 33055011 Review.

2

Open interstitial brachytherapy for the treatment of local-regional recurrences of uterine corpus and cervix cancer after primary surgery.

Monk BJ, Walker JL, Tewari K, Ramsinghani NS, Nisar Syed AM, DiSaia PJ. Monk BJ, et al. Gynecol Oncol. 1994 Feb;52(2):222-8. doi: 10.1006/gyno.1994.1035. Gynecol Oncol. 1994. PMID: 8314143

3

Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature.

Manetta A, Tewari K, Podczaski ES. Manetta A, et al. Gynecol Oncol. 1997 Jul;66(1):20-6. doi: 10.1006/gyno.1997.4725. Gynecol Oncol. 1997. PMID: 9234915 Review.

4

Long-term consequences following conservative management of epithelial ovarian cancer in an infertile patient.

Moore MM, Tewari K, Rose GS, Fruehauf JP, DiSaia PJ. Moore MM, et al. Gynecol Oncol. 1999 Jun;73(3):452-4. doi: 10.1006/gyno.1999.5357. Gynecol Oncol. 1999. PMID: 10366478

5

Biomarker conservation in primary and metastatic epithelial ovarian cancer.

Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP. Tewari KS, et al. Gynecol Oncol. 2000 Aug;78(2):130-6. doi: 10.1006/gyno.2000.5837. Gynecol Oncol. 2000. PMID: 10926791

6

Recent advancements in the treatment of epithelial ovarian cancer.

DiSaia PJ, Tewari KS. DiSaia PJ, et al. Among authors: tewari ks. J Obstet Gynaecol Res. 2001 Apr;27(2):61-75. doi: 10.1111/j.1447-0756.2001.tb01223.x. J Obstet Gynaecol Res. 2001. PMID: 11396641 Review.

7

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP. Tewari KS, et al. Gynecol Oncol. 2005 Sep;98(3):360-8. doi: 10.1016/j.ygyno.2005.04.036. Gynecol Oncol. 2005. PMID: 16000215

8

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ. Gatcliffe TA, et al. Among authors: tewari ks. Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1. Gynecol Oncol. 2009. PMID: 18977518 Clinical Trial.

9

Socioeconomic factors may contribute to neoadjuvant chemotherapy use in metastatic epithelial ovarian carcinoma.

Chase DM, Rincon A, Deane M, Tewari KS, Brewster WR. Chase DM, et al. Among authors: tewari ks. Gynecol Oncol. 2009 Dec;115(3):339-42. doi: 10.1016/j.ygyno.2009.08.008. Epub 2009 Sep 22. Gynecol Oncol. 2009. PMID: 19772939

10

Drug discovery in ovarian cancer.

Chase DM, Mathur N, Tewari KS. Chase DM, et al. Among authors: tewari ks. Recent Pat Anticancer Drug Discov. 2010 Nov;5(3):251-60. doi: 10.2174/157489210791760472. Recent Pat Anticancer Drug Discov. 2010. PMID: 20524931 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters